Precision BioSciences, Inc.
corporate_fare Company Profile
Precision BioSciences, Inc. (NASDAQ:DTIL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for DTIL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for DTIL spans FWP, 8-K, 10-Q, DEF 14A.
Recent high-impact activity:
- $125M Stock Sale Priced at $7.75, Just Above the Last Close
- Precision BioSciences Launches Stock and Pre-Funded Warrant Offering on Heels of Hepatitis B Data
- Precision BioSciences' PBGENE-HBV Hits 100% pgRNA Clearance at 0.4 mg/kg, Moves to Phase 2
- DSMB Clears PBGENE-DMD Safety Review, Allowing Expanded Dosing in Duchenne Trial
- PBGENE-HBV Eliminates cccDNA Evidence in 92% of Evaluable Hep B Patients, Phase 2 Set for Q1 2027
Financial Snapshot
Short Interest & Short Volume
10.52 days to coverFINRA reported short interest of 2,096,967 shares in DTIL as of the October 30, 2026 settlement, a 11.0% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 73.6% of DTIL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for DTIL, detected from its recent SEC filings · based on capital-structure filings through 2026-11-06.
Offering Terms Confirmed · Net Proceeds and Fees
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →